Sa1484 COMBINED NIVOLUMAB PLUS IPILIMUMAB THERAPY CAUSE HIGHER GRADE AND EARLIER IMMUNE-RELATED ADVERSE EVENTS HEPATITIS OCCURRENCE THAN SINGLE AGENT THERAPY